TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25440324

Group type: EXPERIMENTAL
Intervention: 6-month community-based structured program including 2 sessions of exercise training and 1 session of recreation and leisure activities per week (INT; n = 12)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (D-INT; n = 16)
Number of subjects: 28
Study: 25822778

Group type: EXPERIMENTAL
Intervention: Prediction model for ARDS patients requiring mechanical ventilation
Number of subjects: 282
Study: 22901493

Group type: EXPERIMENTAL
Intervention: telephone support (n=241)
Number of subjects: 423

Group type: COMPARATOR
Intervention: home visit (n=182)
Number of subjects: 423
Study: 21310305

Group type: COMPARATOR
Intervention: 0 g of mixed fibers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 g of mixed fibers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 8 g of mixed fibers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 12 g of mixed fibers
Number of subjects: 20
Study: 20027554

Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis to the internal iliac artery
Number of subjects: 38

Group type: COMPARATOR
Intervention: End-to-side anastomosis to the external iliac artery
Number of subjects: 38
Study: 16489964

Group type: EXPERIMENTAL
Intervention: Web-based course for community nurses focusing on evidence-based interventions for postpartum emotional distress
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no web-based course)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Web-based course for community nurses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Experimental centres
Number of subjects: 22
Study: 14579209

Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 155
Study: 11124007

Group type: EXPERIMENTAL
Intervention: 1.33% glyceryl trinitrate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin + 1.33% glyceryl trinitrate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 200
Study: 9804219

Group type: EXPERIMENTAL
Intervention: Micronized 17beta‐oestradiol 4 mg/day with GnRHa suppression
Number of subjects: 106

Group type: COMPARATOR
Intervention: Micronized 17beta‐oestradiol 6 mg/day without GnRHa suppression
Number of subjects: 106
Study: 8014529

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) ketorolac 60 mg (2 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline 2 mL, IM (Control)
Number of subjects: 30
Study: 2809913

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D2 supplementation (2000 IU/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (400 IU/day vitamin D2)
Number of subjects: 81
Study: 973749

Group type: EXPERIMENTAL
Intervention: Parietal Cell Vagotomy (PCV)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Selective vagotomy-antrectomy Billroth I (SV‐A‐BI)
Number of subjects: 92
Study: 30371146

Group type: EXPERIMENTAL
Intervention: 1,500 mg/day of GRE for 3 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (gluten-free cornstarch)
Number of subjects: 11
Study: 29158595

Group type: EXPERIMENTAL
Intervention: Insecticide-resistant strains
Number of subjects: 3324

Group type: EXPERIMENTAL
Intervention: Different developmental stages
Number of subjects: 3324
Study: 25400162

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 535
Study: 22006095

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 156
Study: 21586712

Group type: EXPERIMENTAL
Intervention: Esomeprazole, 20 to 40 mg/d
Number of subjects: 554

Group type: COMPARATOR
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 554

Group type: COMPARATOR
Intervention: LARS
Number of subjects: 554
Study: 19376152

Group type: EXPERIMENTAL
Intervention: Shape-frequency after-effects (SFAE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shape-amplitude after-effects (SAAE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SFAE and SAAE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in SFAE and SAAE from texture-surround inhibition
Number of subjects: 0
Study: 16551904

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol with 67% nitrous oxide (N2O)
Number of subjects: 40
Study: 12919758

Group type: EXPERIMENTAL
Intervention: CLAVE
Number of subjects: 178

Group type: COMPARATOR
Intervention: COS
Number of subjects: 178
Study: 10653385

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sandimmune (SIM)
Number of subjects: 32
Study: 10173369

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide (220 micrograms/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral loratadine (10 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral loratadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physicians' global evaluations
Number of subjects: 0
Study: 8523374

Group type: EXPERIMENTAL
Intervention: Felodipine ER (mean daily dose 11.2 mg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Amlodipine (mean daily dose 7.4 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Felodipine ER
Number of subjects: 118

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 118
Study: 2492354

Group type: EXPERIMENTAL
Intervention: Attachable subcutaneous cuff
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (no cuff)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Polyantibiotic ointment
Number of subjects: 55
Study: 31080037

Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate diet (Diet HP)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Standard hypocaloric diet (Diet S)
Number of subjects: 268
Study: 30641348

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Internet based cognitive‐behavioral therapy
Number of subjects: 737

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Combination with antidepressants
Number of subjects: 737
Study: 28207055

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITNs) distributed at a positive price (increased by $0.55)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Households eligible for free ITNs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Households paying for ITNs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partially subsidized ITNs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ITNs distributed for free or at a small nominal price
Number of subjects: 0
Study: 25347682

Group type: EXPERIMENTAL
Intervention: Walking workstation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cycling workstation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Seated workstation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standing workstation
Number of subjects: 180
Study: 22807519

Group type: EXPERIMENTAL
Intervention: Balapiravir 1500 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Balapiravir 3000 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20978101

Group type: EXPERIMENTAL
Intervention: Euglycemia (glucose clamped to 5 mmol/l)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (glucose clamped to 11 mmol/l)
Number of subjects: 7
Study: 19018048

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 16848150

Group type: EXPERIMENTAL
Intervention: Anterior rectus sheath method
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard mesh repair (Lichtenstein repair)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (anterior rectus sheath and standard mesh repair)
Number of subjects: 62
Study: 12556014

Group type: EXPERIMENTAL
Intervention: Airmax 6 microg, 12 microg, 24 microg, 48 microg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Foradil Aeroliser 12 microg, 24 microg, 48 microg, 96 microg
Number of subjects: 31
Study: 10661337

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with 5-fluorouracil (5-FU) and local-regional radiation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 65
Study: 9488232

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Number of subjects: 64
Study: 8097214

Group type: EXPERIMENTAL
Intervention: Alpidem (25 mg twice daily during tapering)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Alpidem
Number of subjects: 25
Study: 3991284

Group type: EXPERIMENTAL
Intervention: Insurance plans requiring families to pay a percentage of costs (up to 95% coinsurance)
Number of subjects: 1844

Group type: COMPARATOR
Intervention: Free care insurance plan
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Insurance plans requiring families to pay a percentage of costs
Number of subjects: 1844
Study: 31053125

Group type: EXPERIMENTAL
Intervention: Multiple-session peer group training focusing on identifying and addressing barriers to using the guideline
Number of subjects: 66

Group type: COMPARATOR
Intervention: Traditional guideline dissemination (control group)
Number of subjects: 66
Study: 30249424

Group type: EXPERIMENTAL
Intervention: sIPV (high D antigen content)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sIPV (medium D antigen content)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sIPV (low D antigen content)
Number of subjects: 60

Group type: COMPARATOR
Intervention: cIPV
Number of subjects: 60

Group type: COMPARATOR
Intervention: sIPV (CAMS)
Number of subjects: 60
Study: 25257975

Group type: EXPERIMENTAL
Intervention: ≥4 SLC2A9 minor alleles
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: SLC2A9 score increase
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: 0.5mg/dl genetically conferred decrease in serum urate
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: 0.5mg/dl measured decrease in serum urate
Number of subjects: 808
Study: 22738443

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control
Number of subjects: 165
Study: 20660284

Group type: EXPERIMENTAL
Intervention: Hesperidin (800 mg/day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Naringin (500 mg/day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hesperidin and Naringin (both)
Number of subjects: 204
Study: 18520611

Group type: EXPERIMENTAL
Intervention: Dopamine (2 mug/kg per minute)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study: 15777866

Group type: EXPERIMENTAL
Intervention: Functional recovery (defined in terms of neck pain intensity or work disability without medication use)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Neck pain intensity
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Work disability
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sick leave
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Prognostic factors identified by logistic regression analyses
Number of subjects: 125
Study: 12452319

Group type: EXPERIMENTAL
Intervention: Angiotensin II (Ang II) infusion at a constant dose of 50 ng/min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA) infusion with increasing doses (2‐256 ng/min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 36
Study: 10515648

Group type: EXPERIMENTAL
Intervention: Single-point (Liver 3) acupuncture
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8622117

Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg twice daily
Number of subjects: 306

Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily
Number of subjects: 306
Study: 2166857

Group type: EXPERIMENTAL
Intervention: Animal protein diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Animal protein diet supplemented with fiber
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Meat load (acute study)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Soya load (acute study)
Number of subjects: 27
Study: 7049782

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Aspirin + Dipyridamole
Number of subjects: 450
Study: 31944912

Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily activities (Control)
Number of subjects: 0
Study: 31389210

Group type: EXPERIMENTAL
Intervention: Topical Cyclosporine Nanoemulsion 0.05% (CN)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Topical Cyclosporine Emulsion 0.05% (CE)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Diquafosol Sodium 3% (DQ)
Number of subjects: 227
Study: 29233954

Group type: EXPERIMENTAL
Intervention: TPB-based educational intervention
Number of subjects: 578
Study: 25418605

Group type: EXPERIMENTAL
Intervention: Single-dose nilotinib 600 mg with midazolam 4 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Repeated-dose nilotinib 400 mg twice daily with midazolam 2 mg
Number of subjects: 37
Study: 24852508

Group type: EXPERIMENTAL
Intervention: IRC VAS interface
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brimless VAS interface
Number of subjects: 10
Study: 21947558

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 8
Study: 19375008

Group type: EXPERIMENTAL
Intervention: Continuous oral anticoagulation therapy (OAT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Bridging therapy with low-molecular-weight heparin (nadroparin-calcium)
Number of subjects: 214
Study: 17229744

Group type: EXPERIMENTAL
Intervention: Home cueing programme using a prototype cueing device for 3 weeks
Number of subjects: 153
Study: 15107192

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg q.h.s.)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (q.h.s.)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 27
Study: 11544467

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2%)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Levocabastine (0.05%)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9760436

Group type: EXPERIMENTAL
Intervention: Electromagnetic fields (EMF) exposure at power-line frequency (50 Hz)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group of 42 workers of radio link stations, aged 23-65 years (median 30 +/- 14), not exposed to EMF
Number of subjects: 63
Study: 8157552

Group type: EXPERIMENTAL
Intervention: Famciclovir 125 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Famciclovir 750 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Famciclovir (all doses)
Number of subjects: 20
Study: 3064772

Group type: EXPERIMENTAL
Intervention: Various treatments in the DBCG programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recurrence-free survival calculation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survival calculation
Number of subjects: 0
Study: 31675437

Group type: EXPERIMENTAL
Intervention: 2 g probenecid (PRO) + 600 mg tenofovir disoproxil fumarate (TDF) / 400 mg emtricitabine (FTC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 600 mg TDF / 400 mg FTC on day 1 and 300 mg TDF / 200 mg FTC on days 2 and 3 (C IPERGAY)
Number of subjects: 14
Study: 29323459

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 133
Study: 28444112

Group type: EXPERIMENTAL
Intervention: Cobimetinib (60 mg once a day, 21 days on/7 days off) combined with vemurafenib (960 mg twice a day)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Vemurafenib (960 mg twice a day)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Cobimetinib combined with vemurafenib
Number of subjects: 493
Study: 26178731

Group type: EXPERIMENTAL
Intervention: 1350 mg encapsulated green tea extract (540 mg GTC) with 50 mg vitamin C, twice daily for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo, twice daily for 3 months
Number of subjects: 50
Study: 23946601

Group type: EXPERIMENTAL
Intervention: Low dose amitriptyline (10 mg at bedtime) + rabeprazole (20 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-dose rabeprazole (20 mg twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low dose amitriptyline + rabeprazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-dose rabeprazole
Number of subjects: 40
Study: 22118751

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation (640 mg polyphenols/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 35
Study: 18199943

Group type: EXPERIMENTAL
Intervention: Washing with soap and water
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Washing with water alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Drying by patting with a towel
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Drying by rubbing with a towel
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Evaporation drying
Number of subjects: 15
Study: 16989023

Group type: EXPERIMENTAL
Intervention: Pegaptanib (0.3 mg injected into the eye every 6 weeks)
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Pegaptanib
Number of subjects: 1208
Study: 12925219

Group type: EXPERIMENTAL
Intervention: NG‐methyl‐L‐arginine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2,2'‐dipyridyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitric oxide and reactive oxygen species
Number of subjects: 0
Study: 11032267

Group type: EXPERIMENTAL
Intervention: Cisatracurium (CIS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rocuronium (ROC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cisatracurium (CIS) and Rocuronium (ROC)
Number of subjects: 40
Study: 9296229

Group type: EXPERIMENTAL
Intervention: Modified MIC regimen (cisplatin 100 mg/m2 on day 2, ifosfamide on day 1 with mitomycin)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Modified MIC regimen
Number of subjects: 70

Group type: COMPARATOR
Intervention: Previous MIC regimen (cisplatin 120 mg/m2 on day 1)
Number of subjects: 70
Study: 8337736

Group type: EXPERIMENTAL
Intervention: Ivermectin (100 to 200 micrograms/kg body weight)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 3550035

Group type: EXPERIMENTAL
Intervention: Scaling and root planing combined with antiformin-citric acid chemical curettage (SRP/AF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Scaling and root planing alone (SRP)
Number of subjects: 10
Study: 29573894

Group type: EXPERIMENTAL
Intervention: Fluoroscopically aided reductions
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard reductions
Number of subjects: 63
Study: 24721668

Group type: COMPARATOR
Intervention: Type 2 diabetes patients
Number of subjects: 398

Group type: COMPARATOR
Intervention: Type 1 diabetes patients
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Both diabetes groups
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Patients with fractures
Number of subjects: 398
Study: 23245394

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 216

Group type: COMPARATOR
Intervention: Non bivalirudin-based anticoagulants
Number of subjects: 216
Study: 21175545

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 120 µg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS)
Number of subjects: 20
Study: 18410283

Group type: EXPERIMENTAL
Intervention: Midodrine (12.5 mg three times per day for 2 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Albumin (8 g/L of removed ascites)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 24
Study: 15725319

Group type: EXPERIMENTAL
Intervention: Alfentanil (A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil (R)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil-midazolam (RM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alfentanil-midazolam (AM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (all groups)
Number of subjects: 80
Study: 12887341

Group type: EXPERIMENTAL
Intervention: Philips/Jordan HP 735 powered brush
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral‐B40+ manual brush
Number of subjects: 80
Study: 10189005

Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Beta-blocker withdrawal (24 hours after discontinuation of metoprolol)
Number of subjects: 45
Study: 8531308

Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 1861932

Group type: EXPERIMENTAL
Intervention: Iron supplementation at 0, 3, and 6 mg/kg per day for 3 months
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334

Group type: COMPARATOR
Intervention: Iron supplementation and placebo
Number of subjects: 334
Study: 6342354

Group type: EXPERIMENTAL
Intervention: Warfarin plus dipyridamole (400 mg/day)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Warfarin plus aspirin (500 mg/day)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 534
Study: 30660549

Group type: EXPERIMENTAL
Intervention: Radiomic texture analysis (TA) on quantitative cardiovascular magnetic resonance images
Number of subjects: 232

Group type: COMPARATOR
Intervention: Global native T1 mapping
Number of subjects: 232